Bright Minds Biosciences is a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases. Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders. By leveraging the extensive drug discovery experience of the Bright Minds team, we are creating a pipeline of best-in-class 5-HT (serotonin) medicines. Our patented, lead product candidates feature next generation characteristics, reducing unwanted side effects and maximizing therapeutic attributes. Bright Minds compounds are targeted therapies that allow for treatment of specific patient populations.

Recent News

Get the atai
Investor’s Kit now.


Market Cap